Skip to main content
. 2022 Jan 13;8:759311. doi: 10.3389/fmed.2021.759311

Figure 4.

Figure 4

Forest plots of proportion of VMA release in participants receiving ocriplasmin therapy in different groups. (A) In participants without epiretinal membrane (ERM); (B) In participants with ERM; (C) In participants without MH; (D) In participants with MH.